Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2462 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Kim Dao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Ivermectin, Cross-Over Studies, Biological Availability, Tablets. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pediatric Pharmacology and Pharmacometrics Research Center at the University Children's Hospital Basel (UKBB), Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel.
Abstract (Originalsprache)
Ivermectin has been used since the 1980s as an anthelmintic and antiectoparasite agent worldwide. Currently, the only available oral formulation is tablets designed for adult patients. A patient‐friendly orodispersible tablet formulation designed for pediatric use (CHILD‐IVITAB) has been developed and is entering early phase clinical trials. To inform the pediatric program of CHILD‐IVITAB, 16 healthy adults were enrolled in a phase I, single‐center, open‐label, randomized, 2‐period, crossover, single‐dose trial which aimed to compare palatability, tolerability, and bioavailability and pharmacokinetics of CHILD‐IVITAB and their variability against the marketed ivermectin tablets (STROMECTOL) at a single dose of 12 mg in a fasting state. Palatability with CHILD‐IVITAB was considerably enhanced as compared to STROMECTOL. Both ivermectin formulations were well tolerated and safe. Relative bioavailability of CHILD‐IVITAB compared to STROMECTOL was estimated as the ratios of geometric means for C max , AUC 0‐∞ , and AUC 0‐last , which were 1.52 [90% CI: 1.13‐2.04], 1.27 [0.99‐1.62], and 1.29 [1.00‐1.66], respectively. Maximum drug concentrations occurred earlier with the CHILD‐IVITAB formulation, with a median T max at 3.0 h [range 2.0‐4.0 h] versus 4.0 h [range 2.0‐5.0 h] with STROMECTOL ( P = .004). With CHILD‐IVITAB, variability in exposure was cut in half (coefficient of variation: 37% vs 70%) compared to STROMECTOL. Consistent with a more controlled absorption process, CHILD‐IVITAB was associated with reduced variability in drug exposure as compared to STROMECTOL. Together with a favorable palatability and tolerability profile, these findings motivate for further clinical studies to evaluate benefits of such a patient‐friendly ODT formulation in pediatric patients with a parasitic disease, including infants and young children
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Pediatric Pharmacology and Pharmacometrics Research Center, University Children's Hospital Basel (UKBB), Basel, Switzerland.
- Pediatric Infectious Diseases, Children's Hospital of Central Switzerland (KidZ), Lucerne, Switzerland.
- Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
- Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland.
- Division of Clinical Pharmacology & Toxicology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Michael Buettcher, Jonas Kost, Andreas Schittny, Monia Guidi, Thierry Buclin, Jörg Huwyler, Marc Pfister
Förderung
- Pediatric Pharmacology and Pharmacometrics Research Center at the University Children's Hospital Basel (UKBB)
- Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel
Zitieren
APA
Dao, K., Buettcher, M., Golhen, K., Kost, J., Schittny, A., Duthaler, U., Atkinson, A., Haefliger, D., Guidi, M., Bardinet, C., Chtioui, H., Boulekbache, A., Buclin, T., Huwyler, J., Pfister, M., & Rothuizen, L. E. (2024). Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2462
Vancouver
Dao K, Buettcher M, Golhen K, Kost J, Schittny A, Duthaler U, et al. Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2462
BibTeX
@article{Dao2024,
author = {Dao, Kim and Buettcher, Michael and Golhen, Klervi and Kost, Jonas and Schittny, Andreas and Duthaler, Urs and Atkinson, Andrew and Haefliger, David and Guidi, Monia and Bardinet, Carine and Chtioui, Haithem and Boulekbache, Abdelwahab and Buclin, Thierry and Huwyler, Jörg and Pfister, Marc and Rothuizen, Laura E},
title = {Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2462}
}
EUVIMED